According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- SYFOVRE’s (an intravitreal pegcetacoplan injection which is the first and only approved therapy for geographic atrophy (“GA”), a leading cause of blindness) design of clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections;
- as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and
- therefore, defendants’ statements about Apellis’ business, operations, and prospects lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.